N-(1H-indazol-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: N-(1H-indazol-3-yl)-1H-pyrazolo[4,3-d]pyrimidin-3-amine
• 化学式: C₁₂H₉N₇
• 分子量: 251.25
• InChiKey: UYSHYSURIVKRRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.2
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• INHIBITORS OF IMMUNE CHECKPOINT MODULATORS AND RELATED METHODS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20160303124A1

  公开（公告）日：2016-10-20

  The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

  本公开涉及使用MNK特异性抑制剂来抑制免疫抑制组分，例如免疫检查点蛋白PD-1、PD-L1、LAG3和/或免疫抑制性细胞因子，例如IL-10，以抑制或释放某些疾病中的免疫抑制，例如癌症和传染病。
• SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160002245A1

  公开（公告）日：2016-01-07

  The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一种通式I所描述和定义的取代的吡唑并嘧啶基氨基吲唑化合物，以制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作单一药物或与其他活性成分组合使用，治疗或预防过度增殖和/或血管生成紊乱的疾病。
• [EN] SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES<br/>[FR] PYRAZOLOPYRIMIDINYLAMINOINDAZOLES SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2014118226A1

  公开（公告）日：2014-08-07

  The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一种一般式I所述的取代的吡唑吡咯啉基氨基吲哚化合物，以及制备该化合物的方法，用于制备该化合物的中间体化合物，含有该化合物的药物组合物和组合物，以及使用该化合物制备治疗或预防疾病的药物组合物，特别是治疗或预防增生和/或血管生成障碍的药物组合物，作为唯一的药物或与其他活性成分组合使用。
• Inhibitors of immune checkpoint modulators and related methods
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US10702526B2

  公开（公告）日：2020-07-07

  The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.

  本公开涉及使用 MNK 特异性抑制剂来抑制免疫抑制成分，如免疫检查点蛋白 PD-1、PD-L1、LAG3 和/或免疫抑制细胞因子，如 IL-10，以抑制或释放某些疾病（如癌症和传染病）中的免疫抑制。
• INHIBITORS OF IMMUNE CHECKPOINT MODULATORS FOR USE IN TREATING CANCER AND INFECTIONS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：EP3285809B1

  公开（公告）日：2019-09-11